TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Meiji Holdings Co ( (JP:2269) ) has issued an update.
Meiji Holdings Co., Ltd. announced a strategic move to transfer the common stock of its subsidiary, KM Biologics Co., Ltd., to Meiji Seika Pharma Co., Ltd. through an absorption-type company split. This decision is part of the company’s structural reforms to strengthen its pharmaceutical business foundation and enhance integrated operations. By aligning management policies and business strategies, Meiji aims to accelerate its global expansion and develop innovative pharmaceuticals, leveraging the combined expertise of its subsidiaries in infectious diseases. This move is expected to promote faster decision-making and create a more efficient supply system, reinforcing Meiji’s commitment to sustainable growth and social responsibility.
The most recent analyst rating on (JP:2269) stock is a Hold with a Yen3208.00 price target. To see the full list of analyst forecasts on Meiji Holdings Co stock, see the JP:2269 Stock Forecast page.
More about Meiji Holdings Co
Meiji Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and manufacturing of innovative drugs, vaccines, and antibacterial products. The company aims to address social issues such as economic security and infectious disease countermeasures, striving for sustainable growth and fulfilling its social responsibilities.
Average Trading Volume: 1,598,690
Technical Sentiment Signal: Buy
Current Market Cap: Yen875B
See more data about 2269 stock on TipRanks’ Stock Analysis page.